Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
Last Updated: Tuesday, May 7, 2024
Results from population pharmacokinetic (popPK) and exposure–response (ER) analyses on the phase 3 POLARIX study of first-line polatuzumab vedotin plus R-CHP in patients in DLBCL support the use of polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R-CHP for six cycles in patients with previously untreated DLBCL.
Advertisement
News & Literature Highlights
